Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is developing its early-stage cancer diagnostic technology platform. It is cancer diagnostics technology platform leverages "Omics" and machine learning with a focus on how to detect and treat cancers. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Contact
10451 Shellbridge Way
Suite 145
RichmondBCV6X 2W8
CANSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.70 | 5.10 | 0.06% |
| CAC 40 | 8,128.26 | 50.46 | 0.62% |
| DAX 40 | 25,498.09 | 89.45 | 0.35% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,743.27 | 48.02 | 0.45% |
| HKSE | 24,642.51 | 132.42 | 0.54% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 65,877.62 | 486.59 | -0.73% |
| NZX 50 Index | 13,830.68 | 19.57 | 0.14% |
| S&P 500 | 7,743.41 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,679.70 | 14.70 | 0.17% |
| SSE Composite Index | 3,823.62 | 64.75 | -1.67% |